Analysts Anticipate Autolus Therapeutics plc (NASDAQ:AUTL) Will Announce Quarterly Sales of $500,000.00


Share on StockTwits

Analysts expect that Autolus Therapeutics plc (NASDAQ:AUTL) will post sales of $500,000.00 for the current fiscal quarter, according to Zacks Investment Research. Three analysts have made estimates for Autolus Therapeutics’ earnings, with the lowest sales estimate coming in at $300,000.00 and the highest estimate coming in at $820,000.00. Autolus Therapeutics posted sales of $340,000.00 in the same quarter last year, which suggests a positive year-over-year growth rate of 47.1%. The business is scheduled to report its next earnings report on Thursday, May 6th.

On average, analysts expect that Autolus Therapeutics will report full year sales of $1.90 million for the current year, with estimates ranging from $1.00 million to $3.16 million. For the next financial year, analysts forecast that the firm will post sales of $7.56 million, with estimates ranging from $6.90 million to $8.21 million. Zacks Investment Research’s sales calculations are a mean average based on a survey of sell-side analysts that follow Autolus Therapeutics.

Autolus Therapeutics (NASDAQ:AUTL) last issued its quarterly earnings results on Wednesday, March 3rd. The company reported ($0.83) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.77) by ($0.06). Autolus Therapeutics had a negative net margin of 8,652.90% and a negative return on equity of 54.01%. The business had revenue of $0.40 million during the quarter, compared to analyst estimates of $0.43 million.

A number of research firms have commented on AUTL. Mizuho reaffirmed a “buy” rating and set a $24.00 price objective on shares of Autolus Therapeutics in a research note on Wednesday, January 6th. Zacks Investment Research lowered shares of Autolus Therapeutics from a “buy” rating to a “hold” rating in a research note on Tuesday, February 2nd. Redburn Partners reaffirmed a “neutral” rating on shares of Autolus Therapeutics in a research note on Tuesday, March 16th. Truist reduced their price objective on shares of Autolus Therapeutics from $30.00 to $15.00 in a research note on Thursday, January 7th. Finally, HC Wainwright reduced their price objective on shares of Autolus Therapeutics from $19.00 to $13.00 and set a “buy” rating for the company in a research note on Thursday, January 7th. Three research analysts have rated the stock with a hold rating and six have given a buy rating to the company’s stock. The stock presently has a consensus rating of “Buy” and an average price target of $20.22.

Several institutional investors and hedge funds have recently modified their holdings of AUTL. California Public Employees Retirement System increased its holdings in shares of Autolus Therapeutics by 3.2% in the 3rd quarter. California Public Employees Retirement System now owns 41,500 shares of the company’s stock valued at $483,000 after purchasing an additional 1,300 shares during the period. State Street Corp increased its holdings in Autolus Therapeutics by 115.4% in the third quarter. State Street Corp now owns 24,267 shares of the company’s stock worth $282,000 after buying an additional 12,999 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Autolus Therapeutics by 26.9% in the third quarter. JPMorgan Chase & Co. now owns 178,634 shares of the company’s stock worth $2,144,000 after buying an additional 37,879 shares during the last quarter. Pendal Group Limited acquired a new position in Autolus Therapeutics in the fourth quarter worth approximately $450,000. Finally, Wells Fargo & Company MN increased its holdings in Autolus Therapeutics by 62.4% in the fourth quarter. Wells Fargo & Company MN now owns 26,775 shares of the company’s stock worth $239,000 after buying an additional 10,292 shares during the last quarter. Institutional investors own 22.86% of the company’s stock.

AUTL stock traded down $0.25 during mid-day trading on Friday, reaching $5.29. 420,696 shares of the stock traded hands, compared to its average volume of 771,594. Autolus Therapeutics has a 52-week low of $5.10 and a 52-week high of $17.19. The company has a market cap of $276.91 million, a P/E ratio of -1.84 and a beta of 1.75. The stock’s fifty day moving average is $6.19 and its 200-day moving average is $8.84.

About Autolus Therapeutics

Autolus Therapeutics plc, a clinical-stage biopharmaceutical company, develops T cell therapies for the treatment of cancer. The company is developing AUTO1 and AUTO3 for B cell malignancies; AUTO2 and AUTO8 for the treatment of multiple myeloma; AUTO1/22 for the treatment of dual-targeting CAR-T; AUTO3NG for the treatment of hematological cancer; AUTO4 and AUTO5 for T cell lymphoma; AUTO6NG for the treatment of programmed T cell therapies; AUTO6 for the treatment of neuroblastoma; and AUTO7 for the treatment of prostate cancer.

See Also: Short Selling – Explanation For Shorting Stocks

Get a free copy of the Zacks research report on Autolus Therapeutics (AUTL)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Autolus Therapeutics (NASDAQ:AUTL)

Receive News & Ratings for Autolus Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Autolus Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.